CRSP CRISPR Therapeutics AG

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 1:00 p.m. ET.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at . A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics

Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit .

Investor Contact:

Susan Kim



Media Contact:

Rachel Eides





EN
15/02/2024

Underlying

CRSPCRISPR Therapeutics AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CRISPR Therapeutics AG

 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conf...

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT. A live webcast of the fireside chat will be available on the "Events & Presentations" page in t...

November 14, 2024 1 EN
Free Trial
CRSP CRISPR Therapeu...

CRISPR Therapeutics AG: 1 director

A director at CRISPR Therapeutics AG sold 30,000 shares at 55.623USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

CRSP CRISPR THERAPEUTICS AG
11/14/24 November 14, 2024 1 EN
 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare ...

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024, at 2:00 p.m. ET. A live webcast of the fireside chat will be available on the "Events...

November 7, 2024 1 EN
 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics Provides Business Update and Reports Third Quarter...

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results -CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 40 patients have had cells collected across all regions as of mid-October- -Two clinical trials are ongoing for next generation CAR T product candidate, CTX112™ targeting CD19, in B-cell malignancies and systemic lupus erythematos...

November 5, 2024 1 EN
 PRESS RELEASE
Free
CRSP CRISPR Therapeu...

CRISPR Therapeutics Provides Business Update and Reports Second Quarte...

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results -More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications- -Clinical trials opened for CTX112 in systemic lupus erythematosus (SLE) and for CTX131 in hematological malignancies- -Clinical trials ongoing f...

August 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch